The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Inhibiting HbS polymerization to treat SCD: insights from a Phase II trial
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, presents preliminary findings from a Phase II trial (NCT05431088) investigating the efficacy of the next-generation sickle hemoglobin (HbS) polymerization inhibitor GBT021601 for the treatment of patients with sickle cell disease (SCD). The findings indicate good tolerability and a 3 g/dL increase in hemoglobin concentration from baseline. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Advisory board: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Research Funding: Novartis, Forma Therapeutics, GBT/Pfizer
Speakers Bureau: GBT/Pfizer
